Büttner R, Wolf J, Kron A
Institut für Pathologie, Centrum für Integrierte Onkologie Aachen Bonn Köln Düsseldorf, Universität zu Köln, Kerpener Str. 62, 50937, Köln, Deutschland.
Klinik I für Innere Medizin, Centrum für Integrierte Onkologie Aachen Bonn Köln Düsseldorf, Universität zu Köln, Köln, Deutschland.
Pathologe. 2019 May;40(3):276-280. doi: 10.1007/s00292-019-0605-4.
Since 2012, the Network Genomic Medicine (NGM) has been providing a large number of lung cancer patients from referring partner sites with comprehensive molecular-pathological diagnostics on the single diagnostic platform at the University Hospital Cologne. In addition, the network headquarters in Cologne interprets the findings in close interdisciplinary coordination between pathologists and oncologists, provides information on innovative treatment options, and evaluates the personalized therapies using the central database. As part of one of its largest single grants in 2018, the German Cancer Aid (DKH) rolled out this interdisciplinary and intersectoral care model to all existing DKH-funded German comprehensive cancer centers at the time of the initial application.
Presentation of the treatment reality within the national Network Genomic Medicine (nNGM) with its core elements and actors (network centers and intersectoral clinical partners sites).
This article is based on our own experience in NGM and nNGM and includes a summary of the currently applicable guidelines for reimbursement and an overview of the treatment landscape in the field of molecular-pathological diagnostics in Germany.
The focus of nNGM is on the implementation of innovative molecular diagnostics and personalized therapy in broad clinical routine in Germany. This is enabled by developing molecular-pathological diagnostics within the network centers on an ongoing basic, interdisciplinary counseling of referring partner sites, offering innovative clinical trials, and performing central evaluation. In particular, a focus of nNGM is the development of regional networks to treat the affected lung cancer patients close to home at the partner sites whenever possible.
Interdisciplinary teams are essential for the success of a broad implementation of molecular-pathological diagnostics. nNGM addresses a severe deficit in German lung cancer care and in the future will be expanded to further network centers while meeting the defined quality criteria.
自2012年以来，网络基因组医学（NGM）一直在科隆大学医院的单一诊断平台上，为来自转诊合作机构的大量肺癌患者提供全面的分子病理学诊断。此外，科隆的网络总部在病理学家和肿瘤学家之间密切的跨学科协作下解读诊断结果，提供创新治疗方案的信息，并使用中央数据库评估个性化治疗。作为2018年最大单笔资助之一的一部分，德国癌症援助组织（DKH）在首次申请时，将这种跨学科、跨部门的护理模式推广到当时所有由DKH资助的德国综合癌症中心。
介绍国家网络基因组医学（nNGM）中的治疗实际情况及其核心要素和参与者（网络中心和跨部门临床合作机构）。
本文基于我们在NGM和nNGM中的自身经验，包括当前适用的报销指南总结以及德国分子病理学诊断领域治疗情况概述。
nNGM的重点是在德国广泛的临床常规中实施创新的分子诊断和个性化治疗。这通过在网络中心持续开展分子病理学诊断、为转诊合作机构提供跨学科咨询、提供创新临床试验以及进行中央评估来实现。特别是，nNGM的一个重点是发展区域网络，以便尽可能在合作机构为附近的肺癌患者提供治疗。
跨学科团队对于广泛实施分子病理学诊断的成功至关重要。nNGM弥补了德国肺癌护理方面的严重不足，未来将在满足既定质量标准的同时扩展到更多网络中心。
